Screening for Amyloidosis Before Aortic Valve Elective Replacement

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR

NCT06015997

ATTR Amyloidosis Wild Type Severe Aortic Stenosis Aortic Valve Stenosis +1 more

NOT_YET_RECRUITING

Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

NCT07338942

ATTR-CM

NOT_YET_RECRUITING NA

Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis

NCT04636684

Amyloidosis

RECRUITING NA

Atrial Amyloid May Influence Outcomes in Patients Undergoing Surgical Aortic Valve Replacement

NCT07105501

Aortic Stenosis Amyloid

COMPLETED

ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers

NCT07314268

Wild-type ATTR Amyloidosis Amyloidosis Cardiac Amyloidosis, Hereditary +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Untreated cardiac amyloidosis is accompanied with an impaired prognosis. Amyloidosis is often associated with ventricular hypertrophy which leads to severe heart failure and occurs frequently in conjunction with bradycardic or tachycardic malignant arrhythmia. Patients with degenerative aortic valve stenosis suffer more frequently from cardiac ATTR. However, it remains unclear whether the development of aortic stenosis is promoted by ATTR. Due to very similar symptoms (shortness of breath during physical exertion, reduced walking distance) diagnosis of aortic valve stenosis is more often diagnosed in a typical cohort of patients aged between 70-80 years but, in contrast, leads to underdiagnosis of patients with additional cardiac amyloidosis. Six to fifteen percent of patients with aortic valve replacement due to degenerative aortic valve stenosis exhibit a cardiac amyloidosis. Since cardiac amyloidosis without therapeutic intervention is associated with significantly reduced life expectancy, it can be assumed that these patients will not benefit to the same extent from the AVR alone as patients without ATTR. New therapeutic approaches for patients exhibiting ATTR lead to a reduction of mortality and hospitalizations. The primary aim of this study is to establish a simple ATTR screening tool in patients with planned AVR in the clinical routine and, furthermore, to compare the clinical course following AVR between patients with and without ATTR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aortic valve stenosis undergoing aortic valve replacement

Aortic valve stenosis undergoing aortic valve replacement.

The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.

Intervention Type OTHER

We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.

We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥40 years
* written informed consent from the patient or of his/her legal guardian
* hospitalization for AVR due to degenerative aortic valve stenosis